CALC

Rating neutralAI Memo

CalciMedica

As of 2026-08-28/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Pulmonary hypertension clinical and regulatory milestones • 2026-11-26

Base target: $0 / p=50% prob

Biggest risk

CalciMedica remains a clinical-stage biotech without commercial revenue, with a reported Q2 loss worse than analyst expectations and substantial dependence on future financing, trial execution, regulatory progress, and eventual clinical efficacy. The current positive roadmap does not yet offset binary development risk.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The financing and FDA-aligned acute-pancreatitis design give CalciMedica a more defined clinical roadmap than the prior monitoring view. Mid-2027 PAH data and the CM5480 IND could materially improve sentiment if execution and early clinical evidence are favorable.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-28

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Financing and dilution remain central risks
Q2 earnings miss limits near-term support
FDA-aligned acute pancreatitis Phase 2b program

BearKey bullets

Additional financing, dilution, or capital-structure actions may be required despite the recent private placement.
Phase 1b PAH data and the CM5480 IND are not expected until mid-2027, leaving limited near-term fundamental visibility.
The acute-pancreatitis Phase 2b design is FDA-aligned, but clinical efficacy and successful execution remain unproven.

WatchKey bullets

Pulmonary hypertension clinical and regulatory milestones

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $0 (p=50%)

Target spread vs base: +144% / -60%

Scenario probabilities

Bull Target: $1 (p=25%)Base Target: $0 (p=50%)Bear Target: $0 (p=25%)

Commentary

Sentiment is fragile and monitoring-driven. Recent news coverage is sparse, social coverage is unavailable, and analyst revision data are not provided. Stored earnings coverage described a 6.22% pre-market gain despite the Q2 loss miss, suggesting investors focused on financing and the clinical roadmap rather than current earnings [#PR-EARNINGS-2026-08-11]. The low-coverage, micro-cap setting warrants caution and limits confidence in the price scenarios.

As of 2026-08-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Financing and dilution remain central risks
Q2 earnings miss limits near-term support
FDA-aligned acute pancreatitis Phase 2b program

Scenarios

Bull Target (Scenario probability)

$1 / p=25% prob

Base Target (Scenario probability)

$0 / p=50% prob

Bear Target (Scenario probability)

$0 / p=25% prob

Analysis 2026-08-28 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-26
Pulmonary hypertension clinical and regulatory milestones
Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension and a CM5480 IND submission are both anticipated in mid-2027. These are the clearest defined upside milestones in the current company roadmap [#SEC-8K-2026-08-11].
Prob 45.00% • Move 110.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Financing and dilution remain central risks
2026-11-26
The company reported a private placement of up to approximately $49 million, including about $15 million of upfront proceeds, to advance its pulmonary hypertension strategy. Financing improves optionality but leaves capital-structure and execution risk material for a micro-cap biotech [#PR-EARNINGS-2026-08-11].
Prob 65% • Move -25% • Priced-in 55%
Q2 earnings miss limits near-term support
2026-11-26
Stored earnings coverage reported a second-quarter loss of $0.45 per share versus a $0.26 analyst estimate, while net loss widened year over year. The reported positive initial price reaction appeared to prioritize the clinical roadmap and financing over the earnings miss [#PR-EARNINGS-2026-08-11].
Prob 70% • Move -15% • Priced-in 65%

Long-term Catalysts

Months to a year

FDA-aligned acute pancreatitis Phase 2b program
2027-08-28
CalciMedica reported FDA alignment on the Phase 2b Auxora trial design in acute pancreatitis, including a primary endpoint measuring new-onset severe respiratory failure and patient-enrichment work. This creates a clearer development path, but efficacy remains unproven [#SEC-8K-2026-08-11].
Prob 55% • Move 65% • Priced-in 25%

Risks

Additional financing, dilution, or capital-structure actions may be required despite the recent private placement.
Phase 1b PAH data and the CM5480 IND are not expected until mid-2027, leaving limited near-term fundamental visibility.
The acute-pancreatitis Phase 2b design is FDA-aligned, but clinical efficacy and successful execution remain unproven.
The company reported a wider-than-expected Q2 per-share loss and year-over-year net-loss expansion [#PR-EARNINGS-2026-08-11].
The peer set is loose and analyst-target coverage is unavailable, increasing valuation uncertainty.

Peers

Symbol	Summary
ABVC	Loose same-sector micro-cap screen comparable mainly on size; no direct indication or clinical comparability is established in the packet.
ACTU	Loose same-sector micro-cap comparator; valuation is likely event-driven, but the packet does not establish a directly comparable program.
PLRZ	Same-sector market-cap peer from the screen, useful only for illustrating micro-cap biotech volatility and financing sensitivity.
QCLS	Loose sector and size comparator with limited evidence of direct operating comparability.
TXMD	Same-sector market-cap comparator, but the peer set is not sufficiently direct to support a strong relative-valuation conclusion.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-28

Loading AI feed…

Symbol

Summary

ABVC

Loose same-sector micro-cap screen comparable mainly on size; no direct indication or clinical comparability is established in the packet.

ACTU

Loose same-sector micro-cap comparator; valuation is likely event-driven, but the packet does not establish a directly comparable program.

PLRZ

Same-sector market-cap peer from the screen, useful only for illustrating micro-cap biotech volatility and financing sensitivity.

QCLS

Loose sector and size comparator with limited evidence of direct operating comparability.

TXMD

Same-sector market-cap comparator, but the peer set is not sufficiently direct to support a strong relative-valuation conclusion.